Medical University of Viemma
Welcome,         Profile    Billing    Logout  
 6 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kautzky-Willer, Alexandra
Test2Func, NCT03851627: Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

Recruiting
4
32
Europe
Testosterone Undecanoate, Nebido, Placebo, oily solution, Nebido like Placebo
Alexandra Kautzky-Willer, Bayer
Fatty Liver, Overweight/Obesity, Prediabetes/Type2 Diabetes Mellitus, Hypogonadism, Male
09/28
12/28
NCT02817360: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Recruiting
4
2400
Europe, RoW
RAS-antagonist and beta-blocker up-to maximal dosages, Enalapril 40mg/d, Ramipril 10mg/d, Lisinopril 40mg/d, Cilazapril 5mg/d, Perindopril 8mg/d, Captopril 150mg/d, Spirapril 24mg/d, Quinapril 40mg/d, Trandolapril 4mg/d, Zofenopril 60mg/d, Fosinopril 40mg/d, Candesartan 32mg/d, Valsartan 320mg/d, Irbesartan 300mg/d, Losartan 150mg/d, Eprosartan 800mg/d, Bisoprolol 10mg/d, Metoprololsuccinat 200mg/d, Carvedilol 50mg/d (100mg/d if weight is > 85kg), Nebivolol 10mg/d, RAS-antagonist and beta-blocker none or at stable dose
Martin Huelsmann
Heart Diseases, Diabetes Mellitus, Type 2
12/25
12/26
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight and Obesity
02/29
02/29
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Recruiting
3
2620
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
04/25
12/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06245681: Effects of Cross-sex Hormone Treatment on Cardiac Function, Myocardial and Hepatic Fat Content

Recruiting
N/A
40
Europe
gender affirming hormone therapy
Medical University of Vienna
Gender Dysphoria
10/25
10/25
NCT06291675: Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content

Recruiting
N/A
50
Europe
gender-affirming hormone therapy
Medical University of Vienna
Gender Dysphoria, Hormone Therapy Induced Morphologic Change
03/26
03/33
Strametz-Juranek, Jeanette
No trials found
Sabri, Alia
No trials found
Kosi, Lana
No trials found

Download Options